ES2723352T3 - Biomarcadores para la tuberculosis - Google Patents

Biomarcadores para la tuberculosis Download PDF

Info

Publication number
ES2723352T3
ES2723352T3 ES14781260T ES14781260T ES2723352T3 ES 2723352 T3 ES2723352 T3 ES 2723352T3 ES 14781260 T ES14781260 T ES 14781260T ES 14781260 T ES14781260 T ES 14781260T ES 2723352 T3 ES2723352 T3 ES 2723352T3
Authority
ES
Spain
Prior art keywords
sputum sample
interleukin
subject
tuberculosis
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14781260T
Other languages
English (en)
Inventor
Jayne Sutherland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Kingdom Research and Innovation
Original Assignee
United Kingdom Research and Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Kingdom Research and Innovation filed Critical United Kingdom Research and Innovation
Application granted granted Critical
Publication of ES2723352T3 publication Critical patent/ES2723352T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5443—IL-15
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)

Abstract

Un método para la detección de la tuberculosis en un sujeto, que comprende: (a) determinar un nivel de uno o más biomarcadores de proteínas del sistema inmunitario del hospedador en una muestra de esputo obtenida del sujeto, en el que los biomarcadores se seleccionan entre antagonista del receptor de interleucina-1 (IL-1 Ra), interleucina-10 (IL-10), interleucina-13 (IL-13), interleucina-15 (IL-15), factor de crecimiento de fibroblastos (FGF), factor estimulante de colonias de granulocitos (G-CSF) y factor de crecimiento endotelial vascular (VEGF); y (b) comparar los niveles de los biomarcadores en la muestra de esputo con uno o más valores de referencia, comprendiendo dichos uno o más valores de referencia un nivel del biomarcador en una muestra de esputo de un sujeto que no padece tuberculosis; en el que una disminución del nivel de IL-1Ra, IL-10, IL13, IL-15, G-CSF y/o VEGF en la muestra de esputo en comparación con los valores de referencia y/o un aumento del nivel de FGF en la muestra de esputo en comparación con el valor de referencia, son indicativos de la presencia de tuberculosis en el sujeto.
ES14781260T 2013-09-17 2014-09-17 Biomarcadores para la tuberculosis Active ES2723352T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1316524.6A GB201316524D0 (en) 2013-09-17 2013-09-17 Biomarkers
PCT/GB2014/052809 WO2015040377A1 (en) 2013-09-17 2014-09-17 Biomarkers for tuberculosis

Publications (1)

Publication Number Publication Date
ES2723352T3 true ES2723352T3 (es) 2019-08-26

Family

ID=49552785

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14781260T Active ES2723352T3 (es) 2013-09-17 2014-09-17 Biomarcadores para la tuberculosis

Country Status (11)

Country Link
US (1) US20160231333A1 (es)
EP (1) EP3047035B1 (es)
JP (1) JP6648023B2 (es)
CN (1) CN105765079B (es)
AU (1) AU2014322821B2 (es)
BR (1) BR112016005745B1 (es)
CA (1) CA2924405C (es)
ES (1) ES2723352T3 (es)
GB (1) GB201316524D0 (es)
RU (1) RU2697549C2 (es)
WO (1) WO2015040377A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201602305D0 (en) 2016-02-09 2016-03-23 Medical Res Council And Imp Innovations Ltd TB Biomarkers
GB201603367D0 (en) * 2016-02-26 2016-04-13 Ucl Business Plc Method
US11761958B2 (en) 2016-07-12 2023-09-19 Purdue Research Foundation Devices, systems, and methods for the detection of a target analyte using magnetic focus lateral flow immunoassay techniques

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922282A (en) * 1995-06-07 1999-07-13 Ledley; Robert S. Super fast tuberculosis diagnosis and sensitivity testing method
US6136610A (en) * 1998-11-23 2000-10-24 Praxsys Biosystems, Inc. Method and apparatus for performing a lateral flow assay
US20030199685A1 (en) * 2001-03-12 2003-10-23 Monogen, Inc. Cell-based detection and differentiation of disease states
US20030153013A1 (en) * 2002-11-07 2003-08-14 Ruo-Pan Huang Antibody-based protein array system
EP1718973B1 (en) * 2004-02-09 2009-09-09 Rapid Pathogen Screening Inc. Method for the rapid diagnosis of targets in human body fluids
WO2006000045A1 (en) * 2004-06-25 2006-01-05 Proteome Systems Intellectual Property Pty Ltd Novel methods of diagnosis and treatment of m. tuberculosis infection and reagents therefor i
JP2007284362A (ja) * 2006-04-13 2007-11-01 Tokyo Univ Of Science 薬物送達粒子及びその製造方法
JP4406656B2 (ja) * 2007-07-13 2010-02-03 株式会社ビーエル 結核菌検出法
JP5150456B2 (ja) * 2008-11-06 2013-02-20 有限会社アルノテック 結核菌群の薬剤感受性検査法及びキット
AP2011005772A0 (en) * 2008-12-15 2011-06-30 Univ Cape Town Method and device for diagnosing tuberculosis.
US9750789B2 (en) * 2011-02-18 2017-09-05 The Trustees Of Columbia University In The City Of New York Use of matrix metalloproteinase inhibitors to treat tuberculosis

Also Published As

Publication number Publication date
AU2014322821B2 (en) 2020-05-28
CA2924405A1 (en) 2015-03-26
RU2697549C2 (ru) 2019-08-15
BR112016005745B1 (pt) 2020-06-16
GB201316524D0 (en) 2013-10-30
EP3047035A1 (en) 2016-07-27
JP2016539345A (ja) 2016-12-15
CN105765079B (zh) 2020-03-24
EP3047035B1 (en) 2019-02-06
RU2016114503A3 (es) 2018-07-09
AU2014322821A1 (en) 2016-04-07
RU2016114503A (ru) 2017-10-23
JP6648023B2 (ja) 2020-02-14
BR112016005745A2 (pt) 2018-01-30
CN105765079A (zh) 2016-07-13
WO2015040377A1 (en) 2015-03-26
US20160231333A1 (en) 2016-08-11
CA2924405C (en) 2022-04-05

Similar Documents

Publication Publication Date Title
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1119098T1 (el) Αγωνιστες fgfr1 και μεθοδοι χρησης
CO2018003480A2 (es) Una composición para el cuidado bucal con alto contenido de agua que comprende un portador aceptable para la vía oral, fosfato de zinc, fluoruro estañoso y un sistema de amortiguación de ácido orgánico
DK3134123T3 (da) Il-2r-beta-selektive agonister i kombination med et anti-ctla-4-antistof eller et anti-pd-1-antistof
BR112015022490A2 (pt) métodos e composições para classificação de amostras
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
NZ606687A (en) Ratio based biomarkers and methods of use thereof
MX2020010147A (es) Metodos para predecir el riesgo de neumonia intersticial.
BR112014024675A8 (pt) célula hospedeira recombinante, cultura celular
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
ES2723352T3 (es) Biomarcadores para la tuberculosis
EA201692350A1 (ru) Биомаркеры легочной гипертензии
WO2014140362A3 (en) Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc)
FR3004580B1 (fr) Ensemble electrode-electrolyte gel comprenant un materiau carbone poreux et obtenu par voie radicalaire
BR112016006063A2 (pt) método para clarificação de uma colheita de cultura celular em bruto
CL2016003162A1 (es) Predicción de la capacidad del salmón atlántico para utilizar el pigmento dietético basado en la determinación de los polimorfismos.
RU2014124794A (ru) Способ прогнозирования инфекционных осложнений у больных миеломной болезнью
ITPO20130007A1 (it) Metodo e kit per la determinazione rapida della capacita¿ antiossidante totale su sangue intero e altri campioni biologici
UA85502U (ru) Способ оценки прогноза течения хронической болезни почек на фоне хронического пиелонефрита с наличием артериальной гипертензии
RU2014108527A (ru) Способ прогнозирования течения рака молочной железы
AU2014322934A8 (en) Method for evaluating the risk of mortality in patients who exhibit a systemic inflammatory response syndrome (SIRS) or sepsis
UA96322U (uk) Спосіб прогнозування зрощення перелому
UA96968U (uk) Спосіб прогнозування зрощення перелому
UA85809U (uk) Спосіб діагностики загострення бронхіту
UA89621U (ru) Способ прогнозирования развития остеопороза при системной красной волчанке